Feasibility of multidrug resistance (MDR-1) gene transfer in patients undergoing high-dose therapy and peripheral blood stem cell transplantation for lymphoma

Gene Therapy

Volumn 5, Issue 3, 1998, Pages 403-408

  Devereux, S ^a,c   Corney, C ^a   Macdonald, C ^a   Watts, M ^a   Sullivan, A ^a   Goldstone, A H ^a   Ward, M ^b   Bank, A ^b   Linch, D C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Columbia University ^*  (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Gene transfer; Lymphoma; Multidrug resistance; Retrovirus

Indexed keywords

CD34 ANTIGEN; CISPLATIN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ANTIGEN PURIFICATION; APHERESIS; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; CRYOPRESERVATION; GENE TRANSFER; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LYMPHOMA; MULTIDRUG RESISTANCE; PERIPHERAL BLOOD STEM CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

UNIDENTIFIED RETROVIRUS;

EID: 0031909353     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300588     Document Type: Article

References (32)

1. Linch D et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised study. Lancet 1993; 341:1051-1053.
2. Chopra R et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single center 8 year study of 155 patients. Blood 1993; 81: 1137-1145.
3. Philip T et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapysensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333. 1540-1545.
4. Brenner MK et al. Gene marking to determine whether autologous marrow infusion restores long-term hematopoiesis in cancer patients- Lancet 1993; 342: 1134-1137.
5. Dunbar CE et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85: 3048-3057.
6. Kohn DB et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine-deaminase deficiency. Nature Med 1995; 1: 1017-1023.
7. Bertolini F et al Retrovirus-mediated transfer of the mulfidrugresistance-gene into human hematopoietic progenitor cells. Br J Haematol 1994; 88: 318-324.
8. + cells. Blood 1994; 84: 1408-1414.
9. Ward M et al. Retroviral transfer and expression of the human multiple drug resistance (MDR) gene in peripheral blood progenitor cells Clin Cancer Res 1996; 2: 873-876.
10. Podda S et al. Transfer and expression of the human multiple drug resistance gene in live mice. Proc Natl Acad Sci USA 1992; 89: 9676-9680.
11. Sorrentino B et al. Selection of drug resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257: 99-103.
12. Roe T, Reynolds TC, Yu G, Brown PO. Integration of murine leukemia virus DNA depends on mitosis. EMBO J 1993; 12: 2099-2108.
13. Hajihosseini M, lavachev L, Price J. Evidence that retroviruses integrate into post-replication host DNA. EMBO J 1993; 12: 4969-4974.
14. Leitner A et al. Lack of DNA synthesis among CD34(+) cells in cord blood and in cytokine-mobilized blood. Br J Haematol 1996; 92: 255-262.
15. + cells for 6 hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vivo. Blood 1997; 89: 4040-4046.
16. Peters SO, Kittler ELW, Ramshaw HS, Quesenberry PJ. Ex vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL6, IL-11 and stem-cell factor leads to impaired engraftment in irradiated hosts. Blood 1996; 87: 30-37.
17. Watts M et al. Progenitor cell mobilisation after low dose cyclophosphamide and G-CSF: an analysis of progenitor cell quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535-546.
18. Sullivan AM et al. Failure to mobilize peripheral blood stem cells reflects poor quality bone marrow. Br J Haematol 1996; 93: 147.
19. + bone marrow progenitor cells. Blood 1993; 82: 3290-3297.
20. MacDonald C et al. Binding of amphotropic retrovirus to purified CD34 peripheral blood stem cells. Br J Haematol 1996; 93: (Suppl. 1): 48.
21. Hesdorffer C et al. A phase 1 trial of retroviral-mediated transfer of the human MDR-1 gene as marrow chemoprotection in patients undergoing high dose chemotherapy and autologous stem cell transplantation. J Clin Oncol (in press).
22. Jones HM et al. Development of a simplified single apheresis approach for peripheral blood progenitor cell transplantation in previously treated patients with lymphoma. J Clin Oncol 1994; 12- 1693-1702.
23. 2 plus G-CSF. Br J Haematol 1996; 93:167.
24. Cabanillas F, Rodriguez MA. MINE-ESHAP salvage therapy for recurrent and refractory lymphomas. Semin Hematol 1994; 31: 30.
25. Watts MJ et al. Accessory cells do not contribute to G-CSF or IL-6 production nor to rapid hematological recovery following peripheral blood stem cell transplantation. Br J Haematol 1995; 91: 767-772.
26. + cells. Blood 1994; 84: 1408-1414.
27. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988; 167: 400-406.
28. Pastan I et al. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 1988; 85: 4486-4490.
29. Kane S, Gottesman M. Use of multidrug resistance gene in mammalian expression vectors. Meth Enzymol 1993; 217; 34-47.
30. Otto E et al. Characterization of a replication-competent retrovirus resulting from recombination of packaging and vector sequences. Hum Gene Ther 1994; 5: 567-575.
31. Lander MR, Chattopadhyay SK. A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ecotropic, amphotropic, xenotropic, and mink cell focus forming viruses. J Virol 1984; 52: 695-698.
32. Gustincich S et al. A fast method for the isolation of high quality DNA from whole human blood, Biotechniques 1991; 11: 298-301.